BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6247892)

  • 1. Synergistic activation by collagen and 15-hydroxy-9 alpha,11 alpha-peroxidoprosta-5,13-dienoic acid (PGH2) of phosphatidylinositol metabolism and arachidonic acid release in human platelets.
    Rittenhouse SE; Allen CL
    J Clin Invest; 1982 Dec; 70(6):1216-24. PubMed ID: 6816811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet aggregation in whole blood: the role of thromboxane A2 and adenosine diphosphate.
    Carter AJ; Heptinstall S
    Thromb Haemost; 1985 Oct; 54(3):612-6. PubMed ID: 3937261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
    Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
    Fitzpatrick FA; Gorman RR
    Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L; Marcinkiewicz E
    Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulation of human platelet function by prostacyclin and thromboxane A2.
    Gorman RR
    Fed Proc; 1979 Jan; 38(1):83-8. PubMed ID: 215465
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of thromboxane receptors in human platelets.
    Jones RL; Wilson NH; Armstrong RA
    Adv Exp Med Biol; 1985; 192():67-81. PubMed ID: 3010674
    [No Abstract]   [Full Text] [Related]  

  • 9. [Mechanism of action of antiplatelet medication].
    Navarro JL; Frade FJ; Alava I; Obispo T; Trejo R; Jiménez C; Cesar J
    Sangre (Barc); 1984; 29(4-C):817-32. PubMed ID: 6096974
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of thromboxane A2.
    Ambler J; Birch J; Maguire ED; Wallis RB
    Adv Exp Med Biol; 1985; 192():293-308. PubMed ID: 2939695
    [No Abstract]   [Full Text] [Related]  

  • 11. Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators.
    MacIntyre DE; Bushfield M; MacMillan LJ; Moffat KJ; Murdoch FA; Thomson A; Rossi AG; McNicol A
    Agents Actions Suppl; 1986; 20():45-62. PubMed ID: 3028106
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostaglandins and hemostasis: an overview.
    Stuart MJ
    Adv Pediatr; 1983; 30():321-64. PubMed ID: 6231843
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.